Inpatient and outpatient (OP) days and actual clinic visits among nonmyeloablative compared with myeloablative patients with lymphoma or CLL and HCT-CI scores of 0
| Parameters . | Nonmyeloablative patients, mean days plus or minus SD . | Myeloablative patients, mean days plus or minus SD . | P* . | Nonmyeloablative patients, median no. days (range) . | Myeloablative patients, median no. days (range) . | P* . |
|---|---|---|---|---|---|---|
| Inpatient hospitalization | 19.0 ± 43.2 | 23.4 ± 15.7) | .53 | 3.5 (0-232) | 22 (0-61) | .004 |
| OP follow-up | 106 ± 46.6 | 73.6 ± 82.0 | .06 | 97 (19-241) | 64 (0-470) | <.001 |
| OP actual clinic visits | 42.8 ± 21.0 | 27.9 ± 13.3 | .02 | 45 (7-94) | 31 (2-50) | .03 |
| Clinic visits per OP follow-up days | 44.4 ± 16.5 | 38.9 ± 20.8 | .46 | 43.9 (14.8-71.4) | 39.5 (7.2-80.6) | .41 |
| Parameters . | Nonmyeloablative patients, mean days plus or minus SD . | Myeloablative patients, mean days plus or minus SD . | P* . | Nonmyeloablative patients, median no. days (range) . | Myeloablative patients, median no. days (range) . | P* . |
|---|---|---|---|---|---|---|
| Inpatient hospitalization | 19.0 ± 43.2 | 23.4 ± 15.7) | .53 | 3.5 (0-232) | 22 (0-61) | .004 |
| OP follow-up | 106 ± 46.6 | 73.6 ± 82.0 | .06 | 97 (19-241) | 64 (0-470) | <.001 |
| OP actual clinic visits | 42.8 ± 21.0 | 27.9 ± 13.3 | .02 | 45 (7-94) | 31 (2-50) | .03 |
| Clinic visits per OP follow-up days | 44.4 ± 16.5 | 38.9 ± 20.8 | .46 | 43.9 (14.8-71.4) | 39.5 (7.2-80.6) | .41 |
Student t test or Wilcoxon rank sum test.